Urolithin A improves muscle strength and exercise performance in middle-aged adults (Singh et al., 2022)
Human RCT — functional endpoint
Record verify: verified against primary source
| Design | Randomized, double-blind, placebo-controlled trial (functional) |
| DOI | 10.1016/j.xcrm.2022.100633 |
| Citation status | doi verified via Crossref 2026-07-12 (Cell Rep Med 2022;3(5):100633, Singh et al., 'Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults'). PMID and trial registry ID are not confirmed; see identifier status. |
Identifiers: DOI verified; PMID not reported; trial registry id not reported. Record-level verification and identifier-level status are separate: a record can be verified against its primary publication on one identifier while another is simply not confirmed. No identifier is fabricated, and none is left in a “pending” state.
Five-qualifier claim
| Species / population | Middle-aged adults (randomized, placebo-controlled trial). |
| Exposure, route, schedule | Oral urolithin A (500 mg or 1000 mg/day) for 4 months. |
| Comparator / duration | Placebo-controlled, randomized, double-blind; 4-month intervention. |
| Endpoint / numeric result | Improved muscle strength (hamstring) and exercise/endurance performance, with changes in plasma mitochondrial biomarkers (e.g. acylcarnitines) and lower C-reactive protein. |
| What it did NOT establish | A functional-endpoint trial in middle-aged adults — not a lifespan, disease-outcome, or healthy-aging-longevity result. |
Interventions
What this trial administered
These are the compounds this trial administered, nothing more. MitoiX does not rank products, name a best one, or suggest a dose — read the record above and the primary reference, then talk to a clinician.
- Urolithin A (Mitopure) — Urolithin A (Mitopure)
Studied form: Mitopure, 500-1000 mg/day in the human trials
Find Urolithin A (Mitopure) on Amazon →
Links marked with an arrow are affiliate links: MitoiX may earn a commission if you buy through them, at no extra cost to you. This never affects what is published — see the affiliate disclosure.
Primary reference
https://doi.org/10.1016/j.xcrm.2022.100633
Exact identifier confirmed against the primary record via Crossref/ClinicalTrials.gov where stated in the citation status names the source and the date. An identifier that is not confirmed is named as such in the identifier row above, never filled in from a secondary source.